> top > docs > PMC:7204657 > spans > 81-1032 > annotations

PMC:7204657 / 81-1032 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
22 69-73 Gene denotes IL-6 Gene:3569
23 232-240 Species denotes patients Tax:9606
24 667-675 Species denotes patients Tax:9606
25 834-842 Species denotes patients Tax:9606
26 38-49 Chemical denotes tocilizumab MESH:C502936
27 181-192 Chemical denotes tocilizumab MESH:C502936
28 349-360 Chemical denotes Tocilizumab MESH:C502936
29 516-527 Chemical denotes tocilizumab MESH:C502936
30 749-760 Chemical denotes tocilizumab MESH:C502936
31 853-864 Chemical denotes tocilizumab MESH:C502936
32 162-170 Disease denotes COVID-19 MESH:C000657245
33 223-231 Disease denotes COVID-19 MESH:C000657245
34 421-441 Disease denotes rheumatoid arthritis MESH:D001172
35 446-466 Disease denotes giant cell arteritis MESH:D013700
36 581-599 Disease denotes infectious disease MESH:D003141
37 643-657 Disease denotes critically ill MESH:D016638
38 658-666 Disease denotes COVID-19 MESH:C000657245
39 900-914 Disease denotes diverticulitis MESH:D004238

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T2 83-91 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T3 113-121 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T4 452-456 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T5 762-772 Body_part denotes intestinal http://purl.org/sig/ont/fma/fma7199
T6 808-818 Body_part denotes intestinal http://purl.org/sig/ont/fma/fma7199

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T3 162-170 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 223-231 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T5 421-441 Disease denotes rheumatoid arthritis http://purl.obolibrary.org/obo/MONDO_0008383
T6 432-441 Disease denotes arthritis http://purl.obolibrary.org/obo/MONDO_0005578
T7 446-466 Disease denotes giant cell arteritis http://purl.obolibrary.org/obo/MONDO_0008538
T8 457-466 Disease denotes arteritis http://purl.obolibrary.org/obo/MONDO_0043494
T9 581-599 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T10 658-666 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T11 762-784 Disease denotes intestinal perforation http://purl.obolibrary.org/obo/MONDO_0006807
T12 808-830 Disease denotes intestinal perforation http://purl.obolibrary.org/obo/MONDO_0006807
T13 900-914 Disease denotes diverticulitis http://purl.obolibrary.org/obo/MONDO_0004235

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T3 51-52 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T4 246-247 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T5 452-456 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T6 715-716 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T7 762-772 http://purl.obolibrary.org/obo/UBERON_0000160 denotes intestinal
T8 762-772 http://www.ebi.ac.uk/efo/EFO_0000834 denotes intestinal
T9 808-818 http://purl.obolibrary.org/obo/UBERON_0000160 denotes intestinal
T10 808-818 http://www.ebi.ac.uk/efo/EFO_0000834 denotes intestinal
T11 915-918 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T12 933-934 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 38-49 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T2 69-71 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T4 181-192 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T5 516-527 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T6 749-760 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T7 853-864 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T4 0-171 Sentence denotes Zhang et al. [1] discussed the use of tocilizumab, a monoclonal anti-IL-6 receptor antibody, in the treatment of cytokine release syndrome associated with severe COVID-19.
T5 172-348 Sentence denotes Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive hyperinflammatory phenotype, the efficacy and safety of such treatment is unknown.
T6 349-467 Sentence denotes Tocilizumab is primarily used for rheumatological conditions, including rheumatoid arthritis and giant cell arteritis.
T7 468-676 Sentence denotes Rheumatologists have extensive experience using tocilizumab; however, this may not be the case for intensivists, infectious disease specialists, and other physicians treating critically ill COVID-19 patients.
T8 677-789 Sentence denotes Therefore, we would like to highlight a rare but feared complication of tocilizumab: intestinal perforation [2].
T9 790-951 Sentence denotes The mechanism for intestinal perforation in patients receiving tocilizumab is not fully understood, but prior diverticulitis has been noted as a risk factor [2].

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T2 113-138 Phenotype denotes cytokine release syndrome http://purl.obolibrary.org/obo/HP_0033041
T3 421-441 Phenotype denotes rheumatoid arthritis http://purl.obolibrary.org/obo/HP_0001370
T4 457-466 Phenotype denotes arteritis http://purl.obolibrary.org/obo/HP_0012089
T5 762-784 Phenotype denotes intestinal perforation http://purl.obolibrary.org/obo/HP_0031368
T6 808-830 Phenotype denotes intestinal perforation http://purl.obolibrary.org/obo/HP_0031368